Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mucosis, a Dutch vaccine development company, has received a credit line of approximately EUR3m from Agentschap, an agency of the Dutch Ministry of Economic Affairs. Mucosis is expected to use the loan towards the clinical development of its lead product FluGEM, an influenza vaccine that can be administered by a simple spray in the nose.
Subscribe to our email newsletter
According to Mucosis, the loan will be redeemed only if the FluGEM clinical development program is concluded successfully.
Mucosis develops vaccines on the basis of its Mimopath technology, which is based on Lactococcus lactis, a safe bacterium commonly used in the food industry.
Mucosis has developed an easy technique to formulate the L lactis bacteria into non-living particles that can be loaded with antigens from viral, bacterial, or parasitic origin.
The antigen-covered particles form a vaccine that can be delivered into the nose or mouth, without the need for a needle. These vaccines raise protective immunity by activation of both the innate and the adaptive immune system.
Govert Schouten, CEO of Mucosis, said: “We are really pleased with the government’s financial support. This non-dilutive funding underlines the progress we have made so far and, even more importantly, strengthens our financial capabilities going forward. It will enable us to generate proof of efficacy with FluGEM in man”